Regeneron Pharmaceuticals (REGN) Aktievy
Regeneron Pharmaceuticals, Inc. upptäcker, uppfinner, utvecklar, tillverkar och marknadsför läkemedel för behandling av olika sjukdomar över hela världen. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 1/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för REGN från våra riskkontroller.
REGN Community Fair Values
Create NarrativeSee what 167 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Regeneron Pharmaceuticals, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$840.84 |
| 52 veckors högsta | US$844.92 |
| 52 veckors lägsta | US$541.00 |
| Beta | 0.19 |
| 1 månads förändring | 25.10% |
| 3 månaders förändring | 30.85% |
| 1 års förändring | 42.27% |
| 3 års förändring | 0.0036% |
| 5 års förändring | 25.65% |
| Förändring sedan börsintroduktionen | 3,880.31% |
Senaste nyheter och uppdateringar
Recent updates
Uppdatering av berättelse • Aug 17
REGN: Future Oncology Setbacks And Lawsuits Will Restrain Upside Potential
The analyst fair value estimate for Regeneron Pharmaceuticals has increased from $641.00 to $730.00 as analysts factor in recent Q2 beats, higher profit margin expectations, and updated sector models that incorporate stronger trends in key products and the broader biotechnology group. Analyst Commentary Recent research coverage on Regeneron Pharmaceuticals highlights a wide range of views on the stock, with several firms updating their price targets after Q2 results and sector level adjustments.Seeking Alpha • Jul 25
Regeneron: I'm Not Concerned About The Declining ROIC And Operating Margins
Summary Regeneron Pharmaceuticals, Inc. remains a Buy, supported by robust revenue drivers Dupixent and Libtayo, despite recent share price volatility and underperformance versus the S&P. Dupixent’s expanding indications and sustained growth, along with Libtayo’s oncology momentum, underpin forward revenue expectations, even as Eylea faces biosimilar headwinds. Recent margin and ROIC declines are primarily due to accelerated Sanofi repayments and deferred tax asset accumulation, both expected to reverse, improving profitability from Q3 2026. REGN has a strong balance sheet, prudent capital allocation, and a deep pipeline that position REGN for a new growth phase, with operating margins and ROIC likely bottoming in 2026. Read the full article on Seeking Alpha
Uppdatering av berättelse • Jun 24
REGN: Core Immunology Cash Flows Will Support Pipeline And Oncology Upside
Regeneron Pharmaceuticals' updated analyst fair value has shifted lower by about $42 to $833, as analysts factor in reduced expectations for the fianlimab program after recent Phase 3 trial disappointments, softer modeled revenue growth and margins, and a lower assumed future P/E multiple. Analyst Commentary Recent research on Regeneron Pharmaceuticals centers on the impact of fianlimab trial results, competitive pressures around key franchises, and how these factors feed into earnings forecasts and valuation multiples.
Uppdatering av berättelse • Jun 09
REGN: Future Re Rating Will Hinge On Reset Oncology Pipeline Optionality
Analysts have reduced their fair value estimate for Regeneron Pharmaceuticals to $1,000 from $1,030 after a series of lower Street price targets followed the company’s disappointing Phase 3 fianlimab and LAG-3 melanoma trial results. Analyst Commentary Street research following the fianlimab and LAG-3 melanoma trial update has been active, with most recent moves skewed toward lower fair value assumptions and, in some cases, rating downgrades.Uppdatering av berättelse • May 26
REGN: Fair Outlook As LAG 3 Setback Reshapes Pipeline And Product Prospects
Analysts have trimmed their fair value estimate for Regeneron Pharmaceuticals to $641 from $730, reflecting lower assumed profit margins and a reduced future P/E multiple after the recent fianlimab LAG-3 trial setbacks and related cuts to price targets across the Street. Analyst Commentary Street research has turned more cautious on Regeneron following the failed Phase 3 LAG-3 melanoma trial for fianlimab, with a series of reduced price targets and several rating downgrades.Uppdatering av berättelse • May 03
REGN: Expanding Immunology And Gene Therapy Will Support Future Upside
Regeneron's analyst price target has been adjusted slightly higher to $875.31 from $873.78, as analysts factor in updated assumptions around revenue growth, profitability, and future P/E multiples following a mix of recent target hikes and trims across the Street. Analyst Commentary Recent Street research on Regeneron Pharmaceuticals shows a mix of optimism and caution, reflected in a series of price target raises and trims clustered over the past few months.Uppdatering av berättelse • Apr 19
REGN: Fair Outlook As Mixed Pipeline And Product Trends Shape Prospects
Regeneron Pharmaceuticals' updated analyst price target holds at $730, as analysts balance modest tweaks to growth, margins, and discount rate assumptions with recent Street research that broadly reiterates support for Dupixent, the broader pipeline, and capital return from the Sanofi repayment. Analyst Commentary Recent Street research around Regeneron points to a mixed but generally supportive tone, with several firms adjusting price targets and reiterating constructive views on Dupixent, the pipeline, and cash inflows from the Sanofi repayment.Uppdatering av berättelse • Apr 04
REGN: Future Share Re Rating Seen Building On Underappreciated Immunology Pipeline
Analysts have modestly lifted their fair value estimate for Regeneron Pharmaceuticals to $1,030.49. The new estimate is supported by updated models that incorporate Street research pointing to stronger Dupixent contribution, an undervalued pipeline, and slightly higher assumed revenue growth, profit margins, and future P/E levels.Uppdatering av berättelse • Mar 21
REGN: Expanding Immunology Franchise Will Support Future Upside Despite Concentration Risks
Analysts have raised their price targets on Regeneron, with the modelled fair value estimate moving from about $821.12 to $873.78 as they factor in stronger contributions from Dupixent, a higher revenue growth outlook, firmer profit margins, and a slightly lower assumed future P/E multiple. Analyst Commentary Bullish and cautious voices around Regeneron are both active, with recent research focused on how much of Dupixent's profit stream and the broader pipeline are already reflected in the share price.Uppdatering av berättelse • Mar 07
REGN: Fair Outlook As Pipeline Optionality Offsets Product And Competition Risks
Analysts have nudged their average price target for Regeneron higher into the low $900s, reflecting views that Dupixent profitability, indication expansion, and an undervalued pipeline, including Lynozyfic, are not fully reflected in the current share price. Analyst Commentary Recent research on Regeneron centers on whether the market is giving full credit to Dupixent and the broader pipeline versus risks tied to older products and future competition.Uppdatering av berättelse • Feb 21
REGN: Fair Outlook As Future Pipeline And Spending Risks Remain
Analysts have raised their fair value estimate for Regeneron to $730 from $627, reflecting updated models that incorporate higher projected revenue growth, slightly stronger profit margins, and a modestly richer future P/E multiple, in line with a series of recent price target increases across the Street. Analyst Commentary Recent Street research on Regeneron has tilted positive, with a series of higher price targets from firms including Goldman Sachs, Citi, JPMorgan and others.Uppdatering av berättelse • Feb 06
REGN: 2026 Oncology Milestones Are Expected To Drive Share Re Rating
Analysts have nudged our Regeneron Pharmaceuticals fair value estimate higher to US$1,009.20 from US$995.67, reflecting updated price targets that lean on stronger modeled revenue growth assumptions, a modestly adjusted discount rate, slightly lower profit margin expectations, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Regeneron has leaned firmly positive, with a cluster of bullish analysts lifting price targets across a tight time window.Uppdatering av berättelse • Jan 23
REGN: Pipeline Catalysts In 2026 Are Expected To Drive Re Rating
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals from US$890.00 to about US$995.67, reflecting higher modeled revenue growth and profit margins, alongside a slightly lower future P/E assumption and an updated discount rate. Analyst Commentary Recent research on Regeneron Pharmaceuticals has tilted clearly positive, with a series of higher price targets and supportive coverage pointing to confidence in the company’s execution, portfolio strength, and pipeline potential.Uppdatering av berättelse • Jan 09
REGN: Core Franchises And Pipeline Will Support Balanced Upside And Concentration Risks
Analysts have raised their fair value estimate for Regeneron Pharmaceuticals from about $781 to roughly $821. This reflects updated price targets that reference a slightly lower discount rate, modestly adjusted revenue growth assumptions, a small uptick in expected profit margins, and a higher future P/E multiple supported by recent bullish research calls from several major firms.Uppdatering av berättelse • Dec 25
REGN: Future Pipeline And Spending Risks Likely To Pressure Shares
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals to $627 from $543, citing faster expected revenue growth, improved long term profit margins, and a still compelling valuation multiple despite a modestly higher discount rate. Analyst Commentary Recent Street research on Regeneron highlights a generally positive stance on the company, with most firms reiterating or initiating Buy or Outperform ratings and lifting price targets following a strong third quarter.Uppdatering av berättelse • Dec 11
REGN: Core Franchises And Pipeline Will Support Measured Upside Amid Ongoing Risks
Regeneron Pharmaceuticals fair value estimate has been nudged higher to approximately $781 per share from about $768, as analysts factor in stronger medium term revenue growth, expanding profit margins, and a durable innovation led pipeline that supports higher long term earnings power despite modestly lower future multiple assumptions. Analyst Commentary Recent Street research on Regeneron reflects a generally constructive stance, with most firms reiterating or initiating positive ratings while modestly recalibrating price targets around execution risks and spending needs.Uppdatering av berättelse • Nov 27
REGN: Core Franchises And Upcoming Catalysts Will Drive Measured Upside Amid Risks
Regeneron Pharmaceuticals' analyst price target has been increased from approximately $753 to $768, as analysts highlight the company's resilient commercial base, innovative pipeline, and anticipated near-term contributions from core franchises and upcoming catalysts. Analyst Commentary Recent coverage of Regeneron Pharmaceuticals by Wall Street analysts reflects a broad consensus of confidence in the company's long-term growth drivers, while also acknowledging areas of risk that could impact future valuation and execution.Analysartikel • Nov 19
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
The Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) share price has done very well over the last month, posting an...Uppdatering av berättelse • Nov 12
REGN: Positive Trial Results And Approval Will Drive Continued Momentum
Regeneron's analyst price target has increased from approximately $735.72 to $753.17, as analysts cite better-than-expected quarterly results and continued strength across key product lines as drivers for the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts highlight the robust Q3 results, which surpassed expectations for both revenue and earnings.Analysartikel • Nov 09
Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think
Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) stock showed strength, with investors undeterred by its weak earnings...Uppdatering av berättelse • Oct 28
Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead
Regeneron's analyst price target increased from $722.20 to $735.72, reflecting improved earnings results and confidence in the company's drug pipeline, according to recent analyst commentary. Analyst Commentary Following Regeneron Pharmaceuticals' recent earnings results and updates across its drug pipeline, analysts have issued a series of updated price targets and recommendations.Uppdatering av berättelse • Sep 18
Broad Pipeline And Global Access Will Build Future Success
Regeneron Pharmaceuticals’ price target was raised to $722.20 as analysts cited continued outperformance and growth potential for Dupixent and Eylea, strong late-stage trial results in myasthenia gravis, and reinforced market leadership following competitor setbacks. Analyst Commentary Bullish analysts highlighted ongoing strength and growth potential for Dupixent and Eylea, with market share remaining dominant and robust prospects for Eylea HD.Aktieägarnas avkastning
| REGN | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 5.4% | 6.2% | -0.8% |
| 1Y | 42.3% | 46.3% | 20.5% |
Avkastning vs industri: REGN presterade sämre än US Biotechs branschen som gav 46.3 % under det senaste året.
Avkastning vs Marknaden: REGN översteg US marknaden som gav 20.5 % under det senaste året.
Prisvolatilitet
| REGN volatility | |
|---|---|
| REGN Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: REGN har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: REGN s veckovolatilitet ( 4% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1988 | 15,343 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. bedriver forskning, utveckling, tillverkning och marknadsföring av läkemedel för behandling av olika sjukdomar över hela världen. Företaget utvecklar läkemedelskandidater för behandling av ögonsjukdomar, allergiska och inflammatoriska sjukdomar, hjärt- och kärlsjukdomar, metaboliska sjukdomar, neurologiska sjukdomar, infektionssjukdomar och sällsynta sjukdomar, samt cancer och hematologiska tillstånd. Företaget erbjuder även EYLEA-injektioner för våt åldersrelaterad makuladegeneration och diabetiskt makulaödem, myopisk koroidal neovaskularisering, diabetisk retinopati, neovaskulärt glaukom, prematuritetsretinopati, Dupixent-injektion för behandling av atopisk dermatit och astma; Libtayo-injektion för metastaserat eller lokalt avancerat skivepitelcancer i huden; Praluent-injektion för behandling av heterozygot familjär hyperkolesterolemi (HoFH); samt Kevzara-lösning för reumatoid artrit.
Regeneron Pharmaceuticals, Inc. Sammanfattning av grunderna
| REGN grundläggande statistik | |
|---|---|
| Börsvärde | US$80.91b |
| Vinst(TTM) | US$4.33b |
| Intäkter(TTM) | US$15.53b |
19.4x
P/E-förhållande5.4x
P/S-förhållandeÄr REGN övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| REGN resultaträkning (TTM) | |
|---|---|
| Intäkter | US$15.53b |
| Kostnad för intäkter | US$8.63b |
| Bruttovinst | US$6.91b |
| Övriga kostnader | US$2.58b |
| Intäkter | US$4.33b |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 43.35 |
| Bruttomarginal | 44.46% |
| Nettovinstmarginal | 27.86% |
| Skuld/egenkapitalförhållande | 6.3% |
Hur har REGN utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
0.4%
Aktuell utdelningsavkastning9%
UtbetalningskvotGer REGN en tillförlitlig utdelning?
Se REGN utdelningshistorik och jämförelsetal| Regeneron Pharmaceuticals datum för utdelning | |
|---|---|
| Ex utdelningsdag | Aug 18 2026 |
| Utbetalningsdag för utdelning | Aug 31 2026 |
| Dagar till Ex-utdelning | 2 days |
| Dagar till utdelningsdag | 11 days |
Ger REGN en tillförlitlig utdelning?
Se REGN utdelningshistorik och jämförelsetalFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/19 04:31 |
| Aktiekurs vid dagens slut | 2026/08/19 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Regeneron Pharmaceuticals, Inc. bevakas av 55 analytiker. 25 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| Eliana Merle | Barclays |